Market Analysis and Insights: Global Targeted Drugs for Multiple Myeloma Market
The research report studies the Targeted Drugs for Multiple Myeloma market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Targeted Drugs for Multiple Myeloma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Targeted Drugs for Multiple Myeloma Scope and Segment
The global Targeted Drugs for Multiple Myeloma market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Targeted Drugs for Multiple Myeloma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Other
by Application, this report covers the following segments
Hospital
Drug Center
Clinic
Other
Global Targeted Drugs for Multiple Myeloma market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Targeted Drugs for Multiple Myeloma key players in this market include:
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron
The research report studies the Targeted Drugs for Multiple Myeloma market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Targeted Drugs for Multiple Myeloma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Targeted Drugs for Multiple Myeloma Scope and Segment
The global Targeted Drugs for Multiple Myeloma market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Targeted Drugs for Multiple Myeloma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Other
by Application, this report covers the following segments
Hospital
Drug Center
Clinic
Other
Global Targeted Drugs for Multiple Myeloma market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Targeted Drugs for Multiple Myeloma key players in this market include:
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron
1 Market Overview of Targeted Drugs for Multiple Myeloma
1.1 Targeted Drugs for Multiple Myeloma Market Overview
1.1.1 Targeted Drugs for Multiple Myeloma Product Scope
1.1.2 Market Status and Outlook
1.2 Global Targeted Drugs for Multiple Myeloma Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Targeted Drugs for Multiple Myeloma Market Size by Region (2015-2026)
1.4 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Region (2015-2020)
1.5 Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2026)
1.6.1 North America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2026)
1.6.2 Europe Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2026)
1.6.4 Latin America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2026)
2 Targeted Drugs for Multiple Myeloma Market Overview by Type
2.1 Global Targeted Drugs for Multiple Myeloma Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2015-2020)
2.3 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2021-2026)
2.4 Immunomodulator
2.5 Proteasome Inhibitors
2.6 Histone Deacetylase Inhibitors (HDACI)
2.7 Monoclonal Antibody
2.8 Other
3 Targeted Drugs for Multiple Myeloma Market Overview by Application
3.1 Global Targeted Drugs for Multiple Myeloma Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Application (2015-2020)
3.3 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Drug Center
3.6 Clinic
3.7 Other
4 Global Targeted Drugs for Multiple Myeloma Competition Analysis by Players
4.1 Global Targeted Drugs for Multiple Myeloma Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2019)
4.3 Date of Key Manufacturers Enter into Targeted Drugs for Multiple Myeloma Market
4.4 Global Top Players Targeted Drugs for Multiple Myeloma Headquarters and Area Served
4.5 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
4.6 Competitive Status
4.6.1 Targeted Drugs for Multiple Myeloma Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Celgene
5.1.1 Celgene Profile
5.1.2 Celgene Main Business
5.1.3 Celgene Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.1.4 Celgene Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.1.5 Celgene Recent Developments
5.2 Exova
5.2.1 Exova Profile
5.2.2 Exova Main Business
5.2.3 Exova Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.2.4 Exova Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.2.5 Exova Recent Developments
5.3 Natco Pharma
5.5.1 Natco Pharma Profile
5.3.2 Natco Pharma Main Business
5.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.3.4 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.3.5 Intas Pharmaceuticals Recent Developments
5.4 Intas Pharmaceuticals
5.4.1 Intas Pharmaceuticals Profile
5.4.2 Intas Pharmaceuticals Main Business
5.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.4.4 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.4.5 Intas Pharmaceuticals Recent Developments
5.5 Indiabulls Pharmaceutical
5.5.1 Indiabulls Pharmaceutical Profile
5.5.2 Indiabulls Pharmaceutical Main Business
5.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.5.4 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.5.5 Indiabulls Pharmaceutical Recent Developments
5.6 Cipla
5.6.1 Cipla Profile
5.6.2 Cipla Main Business
5.6.3 Cipla Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.6.4 Cipla Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.6.5 Cipla Recent Developments
5.7 Glenmark Pharmaceuticals
5.7.1 Glenmark Pharmaceuticals Profile
5.7.2 Glenmark Pharmaceuticals Main Business
5.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.7.4 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.7.5 Glenmark Pharmaceuticals Recent Developments
5.8 Dr Reddy's Laboratories
5.8.1 Dr Reddy's Laboratories Profile
5.8.2 Dr Reddy's Laboratories Main Business
5.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.8.4 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.8.5 Dr Reddy's Laboratories Recent Developments
5.9 Qilu Pharmaceutical
5.9.1 Qilu Pharmaceutical Profile
5.9.2 Qilu Pharmaceutical Main Business
5.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.9.4 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.9.5 Qilu Pharmaceutical Recent Developments
5.10 Chia Tai-Tianqing
5.10.1 Chia Tai-Tianqing Profile
5.10.2 Chia Tai-Tianqing Main Business
5.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.10.4 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.10.5 Chia Tai-Tianqing Recent Developments
5.11 Hanson Pharm
5.11.1 Hanson Pharm Profile
5.11.2 Hanson Pharm Main Business
5.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.11.4 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.11.5 Hanson Pharm Recent Developments
5.12 Meidakang Huakang Pharmaceutical
5.12.1 Meidakang Huakang Pharmaceutical Profile
5.12.2 Meidakang Huakang Pharmaceutical Main Business
5.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.12.4 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.12.5 Meidakang Huakang Pharmaceutical Recent Developments
5.13 Shandong Kongfu Pharmaceutical
5.13.1 Shandong Kongfu Pharmaceutical Profile
5.13.2 Shandong Kongfu Pharmaceutical Main Business
5.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.13.4 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.13.5 Shandong Kongfu Pharmaceutical Recent Developments
5.14 J&J
5.14.1 J&J Profile
5.14.2 J&J Main Business
5.14.3 J&J Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.14.4 J&J Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.14.5 J&J Recent Developments
5.15 Takeda
5.15.1 Takeda Profile
5.15.2 Takeda Main Business
5.15.3 Takeda Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.15.4 Takeda Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.15.5 Takeda Recent Developments
5.16 Amgen
5.16.1 Amgen Profile
5.16.2 Amgen Main Business
5.16.3 Amgen Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.16.4 Amgen Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.16.5 Amgen Recent Developments
5.17 Bristol Myers Squibb
5.17.1 Bristol Myers Squibb Profile
5.17.2 Bristol Myers Squibb Main Business
5.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.17.4 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.17.5 Bristol Myers Squibb Recent Developments
5.18 Abbvie
5.18.1 Abbvie Profile
5.18.2 Abbvie Main Business
5.18.3 Abbvie Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.18.4 Abbvie Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.18.5 Abbvie Recent Developments
5.19 Seattle Genetics
5.19.1 Seattle Genetics Profile
5.19.2 Seattle Genetics Main Business
5.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.19.4 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.19.5 Seattle Genetics Recent Developments
5.20 Karyopharm Therapeutics
5.20.1 Karyopharm Therapeutics Profile
5.20.2 Karyopharm Therapeutics Main Business
5.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.20.4 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.20.5 Karyopharm Therapeutics Recent Developments
5.21 PDL BioPharma
5.21.1 PDL BioPharma Profile
5.21.2 PDL BioPharma Main Business
5.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.21.4 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.21.5 PDL BioPharma Recent Developments
5.22 Roche
5.22.1 Roche Profile
5.22.2 Roche Main Business
5.22.3 Roche Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.22.4 Roche Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.22.5 Roche Recent Developments
5.23 Sumitomo
5.23.1 Sumitomo Profile
5.23.2 Sumitomo Main Business
5.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.23.4 Sumitomo Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.23.5 Sumitomo Recent Developments
5.24 Merck
5.24.1 Merck Profile
5.24.2 Merck Main Business
5.24.3 Merck Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.24.4 Merck Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.24.5 Merck Recent Developments
5.25 Biogen
5.25.1 Biogen Profile
5.25.2 Biogen Main Business
5.25.3 Biogen Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.25.4 Biogen Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.25.5 Biogen Recent Developments
5.26 Schering-Plough
5.26.1 Schering-Plough Profile
5.26.2 Schering-Plough Main Business
5.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.26.4 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.26.5 Schering-Plough Recent Developments
5.27 Glaxo
5.27.1 Glaxo Profile
5.27.2 Glaxo Main Business
5.27.3 Glaxo Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.27.4 Glaxo Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.27.5 Glaxo Recent Developments
5.28 Chiron
5.28.1 Chiron Profile
5.28.2 Chiron Main Business
5.28.3 Chiron Targeted Drugs for Multiple Myeloma Products, Services and Solutions
5.28.4 Chiron Targeted Drugs for Multiple Myeloma Revenue (US$ Million) & (2015-2020)
5.28.5 Chiron Recent Developments
6 North America
6.1 North America Targeted Drugs for Multiple Myeloma Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Targeted Drugs for Multiple Myeloma Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Targeted Drugs for Multiple Myeloma Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
